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Abstract
As one of the risk factors of cardiovascular diseases, particularly coronary heart disease and 
heart failure, hypertension yields high prevalence not only in developed countries but also 
developing countries. Heart failure as a clinical syndrome manifestation due to deterioration of 
systolic and diastolic ventricular function shows high incidence rate with 11.3 per 1000 population 
per year and 2-3% in prevalence.
Beta blocker is one of the most essentials in the hypertension and heart failure therapy. Beta 
blocker, in particular the selective one shown to reduce the cardiovascular outcome including 
cardiac and cerebrovascular diseases as recent studies reported. Hence, beta blocker is already 
established as fi rst line treatment in guidelines of hypertension and heart failure. Nebivolol as 
the third generation beta blocker shows higher affi nity and selectivity to the beta 1 receptor 
comparing to bisoprolol, metoprolol, and carvedilol. Vasodilatation via L-arginin/Nitric Oxide 
pathway in producing nitric oxide which gives vasodilatory effect on blood vessel also yielded 
by Nebivolol. A meta analysis shows that Nebivolol reducing blood pressure non-inferior to 
other beta blockers, calcium channel blockers and angiotensin converting enzyme inhibitor. A 
large study in geriatric heart failure patient, Nebivolol shows to reduce cardiovascular outcomes 
including mortality and hospitalization with strong evidence. Side effects of beta blocker including 
erectile dysfunction, lipid and metabolism disturbances shows no difference with placebo. 
Furthermore, Nebivolol is also considered safe in COPD patients
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